[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US3883508A - Process for the preparation of guanosine tetra- and penta-phosphates and products - Google Patents

Process for the preparation of guanosine tetra- and penta-phosphates and products Download PDF

Info

Publication number
US3883508A
US3883508A US369657A US36965773A US3883508A US 3883508 A US3883508 A US 3883508A US 369657 A US369657 A US 369657A US 36965773 A US36965773 A US 36965773A US 3883508 A US3883508 A US 3883508A
Authority
US
United States
Prior art keywords
guanosine
diphosphate
phosphate
phosphorothioate
penta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US369657A
Inventor
Alan Frederick Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Hoffmann La Roche Inc
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to US369657A priority Critical patent/US3883508A/en
Application granted granted Critical
Publication of US3883508A publication Critical patent/US3883508A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Definitions

  • ABSTRACT The chemical synthesis of guanosine 3',5'-bisdiphosphate (Magic Spot l) and guanosine 3'- diphosphate, 5'-triphosphate (Magic Spot ll) starting from the readily available guanosine 2,3'-cyclic phosphate is converted in a multistep procedure into the key intermediate guanosine 5'SC C alkyl phosphorothioate-3'-diphosphate which may then be converted into the respective tetraor penta-phosphate in a single step procedure.
  • the tetraand pentaphosphate of guanosine are known enzyme activators particularly enzymes which inactivate antibiotics.
  • the tetraand penta-phosphates of guanosine are useful as adjuncts in screens for compounds with antibiotic activity. These compounds also inhibit protein synthesis in plant materials.
  • the present invention relates to a multistep process for the preparation of guanosine 3,5'-bis-diphosphate (also known as Magic Spot l) and guanosine 3- diphosphate, 5'-triphosphate (also known as Magic Spot ll) starting from guanosine 7.,3 cyclic phosphate.
  • guanosine 2',3' cyclic phosphate which may be in the form of a pyridinium salt, is treated with a C,C-, S-alkylphosphorothioate such as S-ethylphosphorothioate, preferably in the pyridinium form in the presence of a chemical condensing agent such as a carbodiimide derivative.
  • a chemical condensing agent such as a carbodiimide derivative.
  • Suitable carbodiimides for this purpose include diethyl carbodiimide, di-para toluyl carbodiimide and dicyclohexyl carbodiimide. Dicyclohexyl carbodiimide is preferred.
  • This reaction may be conducted at a temperature in the range of from about to 50C., most preferably in the range of from about 20 to 30C.
  • An organic nitrogen base is preferably utilized as solvent in the reaction medium. Suitable organic nitrogen bases for the reaction solvent include pyridine, dimethylformamide, picoline and the like. Pyridine is a preferred solvent.
  • the product obtained from this reaction is guanosine '-SC,C-, alkyl phosphorothioate-2',3'-cyclic phosphate which may be isolated in the form of its base addition salt such as for example its ammonium, alkali metal or trialkylammonium, i.e., triethyl ammonium salt.
  • guanosine 5'- SC,-C-, alkyl phosphorothioate-2,3'-cyclic phosphate is treated in an aqueous reaction medium containing tris hydrochloride buffer at a pH in the range of 7 to 8.5, preferably at about 7.6; with the enzyme ribonuclease T
  • the total of ribonuclease T, utilized is in the range of about 1 X 10 to 1 X 10 units per millirnol of guanosine 5S--C,-C alkyl phosphorothioate- 2',3'-cyclic phosphate employed.
  • This enzyme treatment is conducted at a temperature in the range of from about 25 to 45C., most preferably in the range of from about 35 to 40C.
  • the length of treatment is not broadly critical but generally will be in the range of from about l2 to 60 hours.
  • the resulting product from the enzyme treatment is guanosine 5'SC -C 7 alkyl phosphorothioate-3 -phosphate.
  • the aforesaid guanosine 5'-SC,C alkyl phosphorothioate-3'-phosphate in admixture with a C,-C tetraalkyl ammonium acetate such as tetraethyl ammonium acetate is treated with acetic anhydride.
  • a solution of carbonyl diimidazole in DMF is treated with a solution of carbonyl diimidazole in DMF.
  • a solution of C C trialkyl ammonium phosphate such as tributyl ammonium phosphate in DMF is added.
  • the reaction is conducted for a period of 12 to 100 hours at a temperature in the range of from 0 to 40.
  • guanosine 5'- S-C,-C alkyl phosphorothioate-3"diphosphate This key intermediate may then be converted into either the tetraor penta-phosphate according to the alternative procedures described below.
  • guanosine 5-S-C,-C alkyl phosphorothioate-3-diphosphate into guanosine 3',5'- bis-diphosphate
  • the reaction is conveniently conducted at a temperature in the range of from about 0 to 40C. After a total of 12 to 40 hours with continuous shaking the reaction mixture is worked up in the conventional manner such as for example by column chromatography over DEAE cellulose to yield the desired guanosine 3, 5' bis-diphosphate.
  • the guanosine 5 '-SC,C alkyl phosphorothioate-3'-diphosphate intermediate may be converted into guanosine 3'-diphosphate, 5- triphosphate by treating the former compound preferably as its trialkylammonium salt, with iodine and a C C trialkyl ammonium pyrophosphate, such as tributyl ammonium pyrophosphate, trioctyl ammonium pyrophosphate, dimethylbutyl ammonium pyrophosphate and the like in the dark for 12 to 40 hours at a temperature in the range of from about 0 to 40C.
  • the reaction medium will also contain a cyclic organic nitrogen base such as a a-picoline, pyridine, or other 2- methyl pyridines such as lutidine or collidine, and optionally a trialkylamine such as tributylamine.
  • a cyclic organic nitrogen base such as a a-picoline, pyridine, or other 2- methyl pyridines such as lutidine or collidine, and optionally a trialkylamine such as tributylamine.
  • the tetraand penta-phosphates of guanosine proucked by the process of the present invention are useful as enzyme activators, particularly enzymes which inactivate antibiotics such as chloramphenicol acetyl transferase (CAT) and streptomycin adenylyl transferase (SAT).
  • CAT chloramphenicol acetyl transferase
  • SAT streptomycin adenylyl transferase
  • the aforesaid compounds may be utilized in antibiotic screens wherein compounds to be tested for antibiotic activity are treated with the system comprising a guanosine tetraor penta-phosphate and either CAT or SAT and absence of inactivation is indicative of resistance to these antibiotic inactivating enzymes.
  • guanosine tetraand penta-phosphates produced herein are also inhibitors of protein synthesis in plant material. See Manzocchi et al., FEBS Letters, 29, 309 (1973).
  • alkyl as used herein is meant to include branched or straight chained saturated radicals containing the number of carbon atoms indicated in the prefix.
  • Suitable C -C alkyl groups include methyl, ethyl n-propyl, i-propyl, hexyl, and the like.
  • a preferred C -C alkyl group is ethyl.
  • suitable C C alkyl groups include methyl, ethyl, i-propyl, nbutyl, n-octyl, n-decanyl, and n-hexadecyl. Unless otherwise indicated all alkyl groups are in the normal" configuration.
  • the present invention also relates to the following novel intermediates produced in accordance with the processes disclosed herein:
  • Suitable base addition salts include the alkali metal salts and the C C trialkylammonium salts.
  • the column was eluted with 10% pyridine (500 ml.) and the eluant was evaporated to dryness, and dried by evaporation of portions of pyridine (4 X 50 ml.) over the residue. Pyridine (50 ml.) and dicyclohexylcarbodiimide (4.1 g) were added, and the mixture was shaken for 19 hours. The reaction was terminated by addition of water (50 ml.) and after 4 hours the solids were filtered off and washed with 10% pyridine. The filtrate and washings were evaporated to half volume and diluted to l l. with water.
  • the solution was filtered through celite, diluted to 2 l with water, adjusted to pH 7 with triethylamine, and applied to a DEAE cellulose column (4.5 X 65 cm, bicarbonate form).
  • the column was eluted with a linear gradient of 6 l. of aqueous 0.005M triethylammonium bicarbonate, pH 7.5 in the reservoir. Fractions of 20 ml. were collected, and product guanosine 5'-S-ethyl phosphorothioate-2',3'- cyclic phosphate emerged from the column in fractions 460570.
  • the triethylammonium salt of guanosine 5'-S-ethyl phosphorothioate- 2',3'-cyclic phosphate was obtained as a gum (0.76 mmol, 49%, based on e of 13700 for the guanine moiety).
  • the solution was extracted with ether (3 X 5 ml.), briefly evaporated to remove dissolved ether, and diluted to 65 ml. with water.
  • This solution was applied to a DEAE cellulose column (2.3 X 38 cm, bicarbonate form) which was eluted with a linear gradient of 2 l. of 0.15M triethylammonium bicarbonate buffer pH 7.5 in the mixing vessel and 2 l. of 0.35M buffer in the reservoir. Guanosine 3',5' bisdiphosphate (2.8 umol, 18%) was eluted from the column at a buffer molarity of 0.31M. After removal of the buffer, the product was stored in frozen aqueous solution.
  • the synthetic and natural materials exhibited identical activities in stimulation of in vitro synthesis of the enzyme B-galactosidase.
  • the column was eluted with a linear gradient of l l. of 0.1 M triethylammonium bicarbonate buffer (pH 7.5) in the mixing vessel and l l. of 0.5 M buffer (pH 7.5) in the reservoir.
  • the product was eluted from the column at a buffer strength of 0.33 M.
  • the buffer was removed by evaporation and the product was stored at C.
  • a process for the preparation of guanosine 3,5'- bis-diphosphate which process consists essentially of reacting in the dark guanosine 5'SC -C alkyl phosphorothioate-3-diphosphate with a C -C trialkyl ammonium phosphate in the presence of iodine and in dry pyridine at a temperature in the range of about 0 to 30C. for a period of from about 12 to 40 hours.
  • trialkyl ammonium phosphate is tributyl ammonium phosphate and said guanosine 5'SC,-C alkyl phosphorothioate- 3-diphosphate is guanosine 5'Sethyl phosphoroth- 6 ioate-3 '-diphosphate.
  • a process for the preparation of guanosine-3'- diphosphate, 5'-triphosphate which process consists essentially of reacting in the dark guanosine 5'SC- ,C-, alkyl phosphorothioate-3-diphosphate with a C C trialkyl ammonium pyrophosphate in the presence of iodine and in a mixture of a cyclic nitrogen base and a C C trialkylamine at a temperature in the range of from about 0 to 40C. for a period of from about 12 to 40 hours.
  • the compound of claim 8 which is guanosine 5 '-S- ethyl phosphorothioate-3'-phosphate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)

Abstract

The chemical synthesis of guanosine 3'',5''-bis-diphosphate (Magic Spot I) and guanosine 3''-diphosphate, 5''-triphosphate (Magic Spot II) starting from the readily available guanosine 2'',3''-cyclic phosphate is converted in a multistep procedure into the key intermediate guanosine 5''-S-C1-C7 alkyl phosphorothioate-3''diphosphate which may then be converted into the respective tetra- or penta-phosphate in a single step procedure. The tetraand penta-phosphate of guanosine are known enzyme activators particularly enzymes which inactivate antibiotics. Thus the tetra- and penta-phosphates of guanosine are useful as adjuncts in screens for compounds with antibiotic activity. These compounds also inhibit protein synthesis in plant materials.

Description

United States Patent I19] Cook [ PROCESS FOR THE PREPARATION OF GUANOSINE TETRA- AND PENTA-PHOSPHATES AND PRODUCTS [75] Inventor: Alan Frederick Cook. Cedar Grove,
[73] Assignee: Hoffmann-La Roche Inc., Nutley.
[22] Filed: June 13, 1873 [2]] Appl. No: 369,657
8/1972 Merigan, Jr. et al 260/21 l.5 R
[451 May 13, 1975 Primary Examiner-Johnnie R. Brown Attorney, Agenl, 0r Firm-Samuel L. Welt; Jon S. Suxe; George M. Gould [57] ABSTRACT The chemical synthesis of guanosine 3',5'-bisdiphosphate (Magic Spot l) and guanosine 3'- diphosphate, 5'-triphosphate (Magic Spot ll) starting from the readily available guanosine 2,3'-cyclic phosphate is converted in a multistep procedure into the key intermediate guanosine 5'SC C alkyl phosphorothioate-3'-diphosphate which may then be converted into the respective tetraor penta-phosphate in a single step procedure. The tetraand pentaphosphate of guanosine are known enzyme activators particularly enzymes which inactivate antibiotics. Thus the tetraand penta-phosphates of guanosine are useful as adjuncts in screens for compounds with antibiotic activity. These compounds also inhibit protein synthesis in plant materials.
11 Claims, No Drawings PROCESS FOR THE PREPARATION OF GUANOSINE TETRA- AND PENTA-PI-IOSPHATES AND PRODUCTS DESCRIPTION OF THE INVENTION The present invention relates to a multistep process for the preparation of guanosine 3,5'-bis-diphosphate (also known as Magic Spot l) and guanosine 3- diphosphate, 5'-triphosphate (also known as Magic Spot ll) starting from guanosine 7.,3 cyclic phosphate.
In a first step of the instant process guanosine 2',3' cyclic phosphate, which may be in the form of a pyridinium salt, is treated with a C,C-, S-alkylphosphorothioate such as S-ethylphosphorothioate, preferably in the pyridinium form in the presence of a chemical condensing agent such as a carbodiimide derivative. Suitable carbodiimides for this purpose include diethyl carbodiimide, di-para toluyl carbodiimide and dicyclohexyl carbodiimide. Dicyclohexyl carbodiimide is preferred. This reaction may be conducted at a temperature in the range of from about to 50C., most preferably in the range of from about 20 to 30C. An organic nitrogen base is preferably utilized as solvent in the reaction medium. Suitable organic nitrogen bases for the reaction solvent include pyridine, dimethylformamide, picoline and the like. Pyridine is a preferred solvent. The product obtained from this reaction is guanosine '-SC,C-, alkyl phosphorothioate-2',3'-cyclic phosphate which may be isolated in the form of its base addition salt such as for example its ammonium, alkali metal or trialkylammonium, i.e., triethyl ammonium salt.
In the following step the aforesaid guanosine 5'- SC,-C-, alkyl phosphorothioate-2,3'-cyclic phosphate is treated in an aqueous reaction medium containing tris hydrochloride buffer at a pH in the range of 7 to 8.5, preferably at about 7.6; with the enzyme ribonuclease T The total of ribonuclease T, utilized is in the range of about 1 X 10 to 1 X 10 units per millirnol of guanosine 5S--C,-C alkyl phosphorothioate- 2',3'-cyclic phosphate employed. This enzyme treatment is conducted at a temperature in the range of from about 25 to 45C., most preferably in the range of from about 35 to 40C. The length of treatment is not broadly critical but generally will be in the range of from about l2 to 60 hours. The resulting product from the enzyme treatment is guanosine 5'SC -C 7 alkyl phosphorothioate-3 -phosphate.
In the next reaction step of the instant invention the aforesaid guanosine 5'-SC,C alkyl phosphorothioate-3'-phosphate in admixture with a C,-C tetraalkyl ammonium acetate such as tetraethyl ammonium acetate is treated with acetic anhydride. After dilution with water and passage through a Dowex 50 column in the pyridinium form the reaction residue, after removal of the solvents, is treated with a solution of carbonyl diimidazole in DMF. After quenching with methanol, a solution of C C trialkyl ammonium phosphate such as tributyl ammonium phosphate in DMF is added. The reaction is conducted for a period of 12 to 100 hours at a temperature in the range of from 0 to 40. After workup in a conventional manner there is obtained the desired product, guanosine 5'- S-C,-C alkyl phosphorothioate-3"diphosphate. This key intermediate may then be converted into either the tetraor penta-phosphate according to the alternative procedures described below.
The conversion of guanosine 5-S-C,-C alkyl phosphorothioate-3-diphosphate into guanosine 3',5'- bis-diphosphate can be readily accomplished by treating a dried mixture of guanosine 5'SC,C alkyl phosphorothioate-3'-diphosphate and a C -C trialkyl ammonium phosphate such as tributyl ammonium phosphate (preferred), trioctyl ammonium phosphate, dimethylbutyl ammonium phosphate and the like with iodine in dry pyridine in the dark. The reaction is conveniently conducted at a temperature in the range of from about 0 to 40C. After a total of 12 to 40 hours with continuous shaking the reaction mixture is worked up in the conventional manner such as for example by column chromatography over DEAE cellulose to yield the desired guanosine 3, 5' bis-diphosphate.
Alternatively, the guanosine 5 '-SC,C alkyl phosphorothioate-3'-diphosphate intermediate may be converted into guanosine 3'-diphosphate, 5- triphosphate by treating the former compound preferably as its trialkylammonium salt, with iodine and a C C trialkyl ammonium pyrophosphate, such as tributyl ammonium pyrophosphate, trioctyl ammonium pyrophosphate, dimethylbutyl ammonium pyrophosphate and the like in the dark for 12 to 40 hours at a temperature in the range of from about 0 to 40C. The reaction medium will also contain a cyclic organic nitrogen base such as a a-picoline, pyridine, or other 2- methyl pyridines such as lutidine or collidine, and optionally a trialkylamine such as tributylamine.
The tetraand penta-phosphates of guanosine pro duced by the process of the present invention are useful as enzyme activators, particularly enzymes which inactivate antibiotics such as chloramphenicol acetyl transferase (CAT) and streptomycin adenylyl transferase (SAT). See for example De Crombrugghe et al., Nature New Biology, 241, 237 (1973). Thus the aforesaid compounds may be utilized in antibiotic screens wherein compounds to be tested for antibiotic activity are treated with the system comprising a guanosine tetraor penta-phosphate and either CAT or SAT and absence of inactivation is indicative of resistance to these antibiotic inactivating enzymes.
The guanosine tetraand penta-phosphates produced herein are also inhibitors of protein synthesis in plant material. See Manzocchi et al., FEBS Letters, 29, 309 (1973).
The term alkyl" as used herein is meant to include branched or straight chained saturated radicals containing the number of carbon atoms indicated in the prefix. Suitable C -C alkyl groups include methyl, ethyl n-propyl, i-propyl, hexyl, and the like. A preferred C -C alkyl group is ethyl. Examples of suitable C C alkyl groups include methyl, ethyl, i-propyl, nbutyl, n-octyl, n-decanyl, and n-hexadecyl. Unless otherwise indicated all alkyl groups are in the normal" configuration.
The present invention also relates to the following novel intermediates produced in accordance with the processes disclosed herein:
guanosine 5'S-C,C alkyl phosphorothioate- 2,3'-cyclic phosphate guanosine 5'-S-ethyl phosphorothioate-2',3'-cyclic phosphate guanosine 5'S-C,C alkyl phosphorothioate-3'- phosphate guanosine 5 -S-ethyl phosphorothioate-3'-phosphate diphosphate and the base addition salts thereof. Suitable base addition salts include the alkali metal salts and the C C trialkylammonium salts.
EXAMPLE 1 Guanosine '-S-ethyl phosphorothioate-2',3 '-cyclic phosphate A mixture of dilithium S-ethyl phosphorothioate (15.5 mmol) and guanosine 2',3' cyclic phosphate (1.55 mmol, tributylammonium salt) in pyridine (150 ml.) were stirred with Dowex 50 resin (50 ml., pyridinium form) for 20 minutes and the slurry was added to a Dowex 50 column (2.3 X 35 cm, pyridinium form). The column was eluted with 10% pyridine (500 ml.) and the eluant was evaporated to dryness, and dried by evaporation of portions of pyridine (4 X 50 ml.) over the residue. Pyridine (50 ml.) and dicyclohexylcarbodiimide (4.1 g) were added, and the mixture was shaken for 19 hours. The reaction was terminated by addition of water (50 ml.) and after 4 hours the solids were filtered off and washed with 10% pyridine. The filtrate and washings were evaporated to half volume and diluted to l l. with water. The solution was filtered through celite, diluted to 2 l with water, adjusted to pH 7 with triethylamine, and applied to a DEAE cellulose column (4.5 X 65 cm, bicarbonate form). The column was eluted with a linear gradient of 6 l. of aqueous 0.005M triethylammonium bicarbonate, pH 7.5 in the reservoir. Fractions of 20 ml. were collected, and product guanosine 5'-S-ethyl phosphorothioate-2',3'- cyclic phosphate emerged from the column in fractions 460570. After evaporation to dryness, the triethylammonium salt of guanosine 5'-S-ethyl phosphorothioate- 2',3'-cyclic phosphate was obtained as a gum (0.76 mmol, 49%, based on e of 13700 for the guanine moiety).
EXAMPLE 2 Guanosine 5 '-S-ethyl phosphorothioate-3 '-phosphate A solution of guanosine 5'-S-ethyl phosphorothioate- 2',3'-cyclic phosphate (0.38 mmol) in water ml.) and M tris hydrochloride buffer, pH 7.6 (3 ml.) was treated with ribonuclease T, (500,000 units) for 3 hours at 37. The solution was diluted to 40 ml. with water and applied to a DEAE cellulose column (2.3 X 50 cm, bicarbonate form). The column was eluted with a linear gradient of 4 l. of 0.01M triethylammonium bicarbonate buffer, pH 7.5 in the mixing vessel and 4 l. of 0.2M triethylammonium bicarbonate buffer pH 7.5 in the reservoir. Fractions of ml. were collected, and the product emerged in fractions 183-250. After evaporation of the buffer, the product guanosine 5-S-ethyl phosphorothioate-3'-phosphate was obtained as a gum (0.33 mmol, 88%).
EXAMPLE 3 Guanosine 5 '-S-ethyl phosphorothioate-3 -diphosphate A mixture of guanosine 5'-S ethyl phosphorothioate- 3-phosphate (73 pmol) and tetraethylammonium acetate (200 mg.) were dried by evaporation of pyridine (3 X 2 ml.) from the mixture and treated with acetic anhydride (l ml.) for 66 hours. The solution was cooled to 0 and methanol (0.5 ml.) was added. After 15 min.
water (0.5 ml.) was added and after 2 hours the solution was diluted with water, and passed through a Dowex 50 column (1.5 X 20 cm, pyridinium form). The eluant was evaporated to dryness, dissolved in DMF (0.5 ml.) and treated with a solution of carbonyl diimidazole (58 mg.) in DMF (0.5 ml.). After 18 hours methanol (25 pd) was added, and after 1 hour a solution of tributylammonium phosphate (0.365 mmol) in DMF (0.365 ml.) was added. After 3 days the precipitate was spun down and washed with dry DMF (2 ml.) The combined supernatants were treated with methanol (0.5 ml.), followed by concentrated ammonium hydroxide (25 ml.), in methanol (25 ml.). After 40 hours the solution was evaporated to dryness, dissolved in water (50 ml.) and applied to a DEAE cellulose column 2.3 X 38 gm, bicarbonate form. The column was eluted with a linear gradient of 2 l. of 0.1M triethylammonium bicarbonate pH 7.5 in the mixing vessel and 2 l. of 0.25M triethylammonium bicarbonate pH 7.5 in the reservoir. Fractions of 20 ml. were collected and product guanosine 5'-S-ethylphosphorothioate-3'- diphosphate (26.7 umol, 37%) was obtained in fractions 116-131.
EXAMPLE 4 Guanosine 3',5' bis-diphosphate A mixture of guanosine 5'-S-ethyl phosphorothioate- 3-diphosphate (15.5 umol) and tributylammonium phosphate mol) was dried by evaporation of portions of pyridine (4 X 3 ml.) from the mixture. Dry pyridine (0.5 m1.) and iodine (77 mg.) were added, and the reaction was shaken for 17 hours in the dark. The bulk of the pyridine was removed by evaporation, and the residue was dissolved in 5 ml. triethylammonium bicarbonate buffer (.075 M). The solution was extracted with ether (3 X 5 ml.), briefly evaporated to remove dissolved ether, and diluted to 65 ml. with water. This solution was applied to a DEAE cellulose column (2.3 X 38 cm, bicarbonate form) which was eluted with a linear gradient of 2 l. of 0.15M triethylammonium bicarbonate buffer pH 7.5 in the mixing vessel and 2 l. of 0.35M buffer in the reservoir. Guanosine 3',5' bisdiphosphate (2.8 umol, 18%) was eluted from the column at a buffer molarity of 0.31M. After removal of the buffer, the product was stored in frozen aqueous solution.
The synthetic guanosine 3',5' bis-diphosphate and material from natural sources (prepared by the procedure of Cashel et al., J. Biol. Chem. 245, 2309 (1970) had identical mobilities in the following systems:
1. Polyethyleneimine cellulose thin layer chromatography (ascending), solvent 1.5M potassium phosphate, pH 3.5.
2. Paper electrophoresis, Whatman No. 3 paper, so-
dium citrate, 0.05M, pH 5, l500v, 1.75 hr.
The synthetic and natural materials exhibited identical activities in stimulation of in vitro synthesis of the enzyme B-galactosidase.
EXAMPLE 5 Guanosine 3 -diphosphate, 5'-triphosphate Guanosine 5'-S-ethyl phosphorothioate 3'- ml) and iodine (191 mg) for 18 hr in the dark. The product was partitioned between aqueous triethylammonium bicarbonate buffer, pH 7 (0.05 M, 50 ml) and ether (50 ml), and the aqueous layer was washed with ether (2 X 50 ml), diluted with triethylammonium bicarbonate buffer, pH 7.5 (0.IM, I00 ml) and applied to a DEAE cellulose column (36 X L3 cm, bicarbonate form). The column was eluted with a linear gradient of l l. of 0.1 M triethylammonium bicarbonate buffer (pH 7.5) in the mixing vessel and l l. of 0.5 M buffer (pH 7.5) in the reservoir. The product was eluted from the column at a buffer strength of 0.33 M. The buffer was removed by evaporation and the product was stored at C.
Paper chromatography lsobutyric acid/conc ammonia/water 57:4:39 (v/v/v) for 3 days Product Guanosine 3-diphosphate, 5'-triphosphate Guanosine 3',5 '-bis-diphosphate Rf 0.40
1 claim:
1. A process for the preparation of guanosine 3,5'- bis-diphosphate which process consists essentially of reacting in the dark guanosine 5'SC -C alkyl phosphorothioate-3-diphosphate with a C -C trialkyl ammonium phosphate in the presence of iodine and in dry pyridine at a temperature in the range of about 0 to 30C. for a period of from about 12 to 40 hours.
2. The process of claim 1 wherein said trialkyl ammonium phosphate is tributyl ammonium phosphate and said guanosine 5'SC,-C alkyl phosphorothioate- 3-diphosphate is guanosine 5'Sethyl phosphoroth- 6 ioate-3 '-diphosphate.
3. A process for the preparation of guanosine-3'- diphosphate, 5'-triphosphate which process consists essentially of reacting in the dark guanosine 5'SC- ,C-, alkyl phosphorothioate-3-diphosphate with a C C trialkyl ammonium pyrophosphate in the presence of iodine and in a mixture of a cyclic nitrogen base and a C C trialkylamine at a temperature in the range of from about 0 to 40C. for a period of from about 12 to 40 hours.
4. The process of claim 3 wherein said cyclic nitrogen base is a-picoline and said C -C trialkylamine is tributylamine.
5. The process of claim 3 wherein said guanosine 5'SC,C-, alkyl phosphorothioate-3-diphosphate is 5'-S-ethyl phosphorothioate-3-diphosphate and said C -C trialkyl ammonium pyrophosphate is tributyl ammonium pyrophosphate.
6. Guanosine 5'SC,-C-, alkyl phosphorothioate- 2',3'-cyclic phosphate and its base addition salts.
7. The compound of claim 6 which is guanosine 5-S- ethyl phosphorothioate-2',3'-cyclic phosphate.
8. Guanosine 5'S--C,-C alkyl phosphorothioate- 3'-phosphate and its base addition salts.
9. The compound of claim 8 which is guanosine 5 '-S- ethyl phosphorothioate-3'-phosphate.
10. Guanosine 5'SC,-C alkyl phosphorothioate-3'-diphosphate and its base addition salts.
11. The compound of claim 10 which is guanosine 5 -S-ethyl phosphorothioate-3"diphosphate.

Claims (11)

1. A process for the preparation of guanosine 3'',5''-bis-diphosphate which process consists essentially of reacting in the dark guanosine 5''-S-C1-C7 alkyl phosphorothioate-3''-diphosphate with a C1-C16 trialkyl ammonium phosphate in the presence of iodine and in dry pyridine at a temperature in the range of about 0* to 30*C. for a period of from about 12 to 40 hours.
2. The process of claim 1 wherein said trialkyl ammonium phosphate is tributyl ammonium phosphate and said guanosine 5''-S-C1-C7 alkyl phosphorothioate-3''-diphosphate is guanosine 5''-S-ethyl phosphorothioate-3''-diphosphate.
3. A process for the preparation of guanosine-3''-diphosphate, 5''-triphosphate which process consists essentially of reacting in the dark guanosine 5''-S-C1-C7 alkyl phosphorothioate-3-diphosphate with a C1-C16 trialkyl ammonium pyrophosphate in the presence of iodine and in a mixture of a cyclic nitrogen base and a C1-C16 trialkylamine at a temperature in the range of from about 0* to 40*C. for a period of from about 12 to 40 hours.
4. The process of claim 3 wherein said cyclic nitrogen base is Alpha -picoline and said C1-C16 trialkylamine is tributylamine.
5. The process of claim 3 wherein said guanosine 5''-S-C1-C7 alkyl phosphorothioate-3-diphosphate is 5''-S-ethyl phosphorothioate-3-diphosphate and said C1-C16 trialkyl ammonium pyrophosphate is tributyl ammonium pyrophosphate.
6. GUANOSINE 5''-S-C1-C7 ALKYL PHOSPHOROTHIOATE-2'',3''CYCLIC PHOSPHATE AND ITS BASE ADDITION SALTS.
7. The compound of claim 6 which is guanosine 5-S-ethyl phosphorothioate-2'',3''-cyclic phosphate.
8. Guanosine 5''-S-C1-C7 alkyl phosphorothioate-3''-phosphate and its base addition salts.
9. The compound of claim 8 which is guanosine 5''-S-ethyl phosphorothioate-3''-phosphate.
10. Guanosine 5''-S-C1-C7 alkyl phosphorothioate-3''-diphosphate and its base addition salts.
11. The compound of claim 10 which is guanosine 5''-S-ethyl phosphorothioate-3''-diphosPhate.
US369657A 1973-06-13 1973-06-13 Process for the preparation of guanosine tetra- and penta-phosphates and products Expired - Lifetime US3883508A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US369657A US3883508A (en) 1973-06-13 1973-06-13 Process for the preparation of guanosine tetra- and penta-phosphates and products

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US369657A US3883508A (en) 1973-06-13 1973-06-13 Process for the preparation of guanosine tetra- and penta-phosphates and products

Publications (1)

Publication Number Publication Date
US3883508A true US3883508A (en) 1975-05-13

Family

ID=23456361

Family Applications (1)

Application Number Title Priority Date Filing Date
US369657A Expired - Lifetime US3883508A (en) 1973-06-13 1973-06-13 Process for the preparation of guanosine tetra- and penta-phosphates and products

Country Status (1)

Country Link
US (1) US3883508A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2331350A1 (en) * 1975-11-14 1977-06-10 Hoechst Ag Nucleotides polyphosphorylated at two positions - which inhibit the growth of tumours
US4171318A (en) * 1978-08-24 1979-10-16 Hoffmann-La Roche Inc. Fluorinated polyenes
US4231944A (en) * 1975-11-14 1980-11-04 Hoffmann-La Roche Inc. Fluorinated polyenes
US4299995A (en) * 1979-05-10 1981-11-10 Hoffmann-La Roche Inc. Fluorinated polyenes
US4335248A (en) * 1975-11-14 1982-06-15 Hoffmann-La Roche Inc. Fluorinated polyenes
US4395575A (en) * 1975-11-14 1983-07-26 Hoffmann-La Roche, Inc. 5(Halophenyl)-2-fluoro-pentadienals
US5625056A (en) * 1992-05-26 1997-04-29 Biolog Life Science Institute Derivatives of cyclic guanosine-3',5'-monophosphorothioate
WO2000062803A2 (en) * 1999-04-15 2000-10-26 Board Of Regents, The University Of Texas System ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467648A (en) * 1966-07-28 1969-09-16 Waldhof Zellstoff Fab Process for the preparation of nucleoside phosphate
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467648A (en) * 1966-07-28 1969-09-16 Waldhof Zellstoff Fab Process for the preparation of nucleoside phosphate
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2331350A1 (en) * 1975-11-14 1977-06-10 Hoechst Ag Nucleotides polyphosphorylated at two positions - which inhibit the growth of tumours
US4231944A (en) * 1975-11-14 1980-11-04 Hoffmann-La Roche Inc. Fluorinated polyenes
US4335248A (en) * 1975-11-14 1982-06-15 Hoffmann-La Roche Inc. Fluorinated polyenes
US4395575A (en) * 1975-11-14 1983-07-26 Hoffmann-La Roche, Inc. 5(Halophenyl)-2-fluoro-pentadienals
US4171318A (en) * 1978-08-24 1979-10-16 Hoffmann-La Roche Inc. Fluorinated polyenes
US4299995A (en) * 1979-05-10 1981-11-10 Hoffmann-La Roche Inc. Fluorinated polyenes
US5625056A (en) * 1992-05-26 1997-04-29 Biolog Life Science Institute Derivatives of cyclic guanosine-3',5'-monophosphorothioate
WO2000062803A2 (en) * 1999-04-15 2000-10-26 Board Of Regents, The University Of Texas System ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS
WO2000062803A3 (en) * 1999-04-15 2001-01-18 Univ Texas ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS

Similar Documents

Publication Publication Date Title
US3883508A (en) Process for the preparation of guanosine tetra- and penta-phosphates and products
US3336289A (en) 9-beta-d-ribofuranosyl-7-deazapurine 5'-phosphate esters
US4210746A (en) Nucleotide inhibitor of protein synthesis
Jones et al. Chemical synthesis of 5'-O-triphosphoryladenylyl-(2'. fwdarw. 5')-adenylyl-(2'. fwdarw. 5')-adenosine (2-5A)
McGuigan et al. Kinase bypass: a new strategy for anti-HIV drug design
Neufeld et al. Enzymic phosphorylation of D-glucuronic acid by extracts from seedlings of Phaseolus aureus
Rosowsky et al. Methotrexate analogs. 10. Direct coupling of methotrexate and diethyl L-glutamate in the presence of peptide bond-forming reagents
US3300479A (en) Deazapurine riboside cyclic 3', 5'-phosphates and process therefor
Shealy et al. Cyclopentyl derivatives of 8‐azahypoxanthine and 8‐azaadenine. Carbocyclic analogs of 8‐azainosine and 8‐azaadenosine
Ohtsuka et al. Transfer ribonucleic acids and related compounds. II. A method for synthesis of protected ribooligonucleotides using a ribonuclease
Tsou et al. Indigogenic phosphodiesters as potential chromogenic cancer chemotherapeutic agents
Sugiura et al. The Synthesis of 3′-Phosphate and 2′, 3′-Cyclic Phosphate of 2-Amino-4-hydroxy-6-(1′, 2′, 3′-trihydroxypropyl) pteridine
Srivastava et al. Synthesis and biological evaluation of certain 2'-deoxy-. beta.-D-ribo-and 2. beta.-D-arabinofuranosyl nucleosides of purine-6-carboxamide and 4, 8-diaminopyrimido [5, 4-d] pyrimidine
FURUKAWA et al. A Direct Synthesis of 3', 5'-Di-O-acetyl-O2, 2'-cyclouridine
Huennekens et al. A NEW CHEMICAL SYNTHESIS OF FLAVIN-ADENINE-DINUCLEOTIDE AND ANALOGS1, 2
Mizuno et al. Nucleotides. V. Syntheses of 2'-O-and 3'-O-(3-methyl-2-picolyl 1-oxide) ribonucleosides and diribonucleoside monophosphates by application of 3-methyl-2-picolyl 1-oxide protection
Shuto et al. New Neplanocin Analogues II. Enzymatic One-Step Synthesis and Antitumor Activity of 6′-(3-sn-Phosphatidyl) Neplanocin a Derivatives
Ikehara et al. Seven-membered cyclic phosphate: synthesis and properties of S-cycloadenosine 2′ 5′-cyclic phosphate and cordycepin 2′, 5′-cyclic phosphate. Studies of nucleosides and nucleotides. LXIV′ l). Purine cyclonucleosides 25.
JPH0931092A (en) Production of 2'-3'-di-o-acyl atp
Hoffmann et al. Synthesis and reactivity of intermediates formed in the T4 RNA ligase reaction
Marutzky et al. ATP-analogues as substrates for the leucyl-tRNA synthetase from Escherichia coli MRE 600
Hampton et al. Design of substrate-site-directed irreversible inhibitors of adenosine 5'-phosphate aminohydrolase. Effect of substrate substituents on affinity for the substrate site
Rowe et al. Synthesis of 3′–5′ dinucleotides with RNase T1
US4446315A (en) Adenosine 5'-triphosphate-4-carboxamide-ribofuranosylthiazole
Nagyvary et al. Arabinonucleotides III. The conversion of cytidylic acid into aracytidine-3′ phosphate at low temperature